ADC Therapeutics (ADCT) Operating Leases: 2019-2023
Historic Operating Leases for ADC Therapeutics (ADCT) over the last 4 years, with Sep 2023 value amounting to $10.1 million.
- ADC Therapeutics' Operating Leases rose 52.16% to $10.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $10.1 million, marking a year-over-year increase of 52.16%. This contributed to the annual value of $6.6 million for FY2022, which is 18.19% down from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Operating Leases is $10.1 million, which was down 6.37% from $10.8 million recorded in Q2 2023.
- ADC Therapeutics' Operating Leases' 5-year high stood at $11.0 million during Q1 2023, with a 5-year trough of $2,605 in Q3 2020.
- Over the past 3 years, ADC Therapeutics' median Operating Leases value was $7.6 million (recorded in 2021), while the average stood at $8.0 million.
- Per our database at Business Quant, ADC Therapeutics' Operating Leases surged by 275,638.96% in 2021 and then declined by 21.31% in 2022.
- Over the past 5 years, ADC Therapeutics' Operating Leases (Quarterly) stood at $5.0 million in 2019, then reached $2,605 in 2020, then surged by 275,638.96% to $8.0 million in 2021, then decreased by 18.19% to $6.6 million in 2022, then spiked by 52.16% to $10.1 million in 2023.
- Its last three reported values are $10.1 million in Q3 2023, $10.8 million for Q2 2023, and $11.0 million during Q1 2023.